HARTECH Corporation

The Opportunity

In March 1996, President Clinton issued a National Performance Review titled "Reinventing the Regulation of Cancer Drugs, Accelerating Approval and Expanding Access". This opened the door for a whole new wave of drug testing and usage. The Bactobridge H₃ is a key component of the Individualized Patient Anti-Cancer Treatment Project currently underway at the Department of Medical and Research Technology (DMRT), University of Maryland School of Medicine. Fresh samples of patient’s tumor from surgery or a biopsy will be tested with various drugs. Drugs that are most effective in killing the cancer cells will be recommended for treatment.

In April 1998, the Maryland General Assembly voted to require health insurers to pay the cost of coverage for patients participating in medical clinical trials for cancer and other life-threatening diseases. Also on January 1, 1999, the meat and poultry industries will enter into the 2^nd phase of compliance with new microbial testing requirements imposed by the USDA/FSIS HACCP Program. The food industry is anticipated to spend over $700 million in the next two years to meet those requirements.

The Product

The Bactobridge H₃ is a re-engineering of proven products enhanced with the latest technological improvements to provide functionality essential to a wide range of applications. The ongoing developments in cancer research and food industry testing will create a tremendous demand for our product. DMRT has completed Phase #1 of product testing of the Bactobridge H₃ in a beta-testing manner for microbiological data collection, analysis and it's application in the food industry. Comparison of competitive products and product evaluation to determine reliability and accuracy of the Bactobridge H₃ has also been completed by DMRT whose findings suggest clear advantages with minimal comparable products existing. They have consistently demonstrated the benefits of using the Bactobridge H₃ in a non-invasive; non-destructive method for determining quantitative analysis of suspected foodborne pathogens in specimens coming from commercial food processors

The Rewards

The time is NOW!

New laboratories will need the Bactobridge H₃ - existing laboratories will benefit from upgrading their methods. The government has mandated microbial testing and patients deserve access. Check out our product, contact the Company for a copy of the Preliminary Offering Circular and decide if you want to participate in the opportunity.

Click here to review the online version of the Preliminary Offering Circular.

To Purchase Stock

You can have your stock broker contact the Company's Registrar and Transfer Agent:

Chase Mellon Shareholder Service
450 West 33^rd Street
15^th Floor
New York, NY 10001-2697
Telephone (212) 046-7187

Or place your stock order directly with the Company

William L. Robinson, Jr., Chairman & CEO
or
Dr. R. Benjamin Dawson, M.D.
at
HARTECH Corporation
1 East Chase Street
Suites 1112 & 1113
Baltimore, MD 21201
Phone # (410) 244-6570 or (410) 244-6580
Fax (410) 244-6620
E-mail Address [email protected]

This information does not constitute an offer to sell securities.
The solicitation of an offer to buy the securities offered
may be made only by means of an official Offering Circular.
A copy of the Offering Circular may be obtained by contacting the company.


These securities will be offered in the State of Maryland.
Offers in other states will begin upon qualification or registration in that state.

View "Real-time Pathogen and Human Tumor Cell Sensitivity Detection
Technology to Improve Food Safety"

Products

Beta Testing/Clinical Trial Center

View Valuation of Bactobridge Technology

Return to Executive Summary

Go to Hartech's Home Page